Organization · Venture Capital
CHV
Catalyst Health Ventures (CHV) is a Boston-based venture capital firm specializing in early-stage investments in transformative medical technologies. The firm focuses on MedTech, partnering with entrepreneurs to navigate the complexities of healthcare.
Overview
What CHV does
What CHV is
Catalyst Health Ventures (CHV) is a Boston-based venture capital firm specializing in early-stage investments in transformative medical technologies. The firm focuses on MedTech, partnering with entrepreneurs to navigate the complexities of healthcare.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 1998
- Approximate age
- About 28 years
- Structured capabilities
- Funder
- Last reviewed
- May 1, 2026
Official channels
Find CHV elsewhere
Open the official website or a supported primary organization account.
Capability profile
CHV as a funder
Investment thesis
Catalyst Health Ventures invests in visionary teams developing breakthrough medical technologies that address significant clinical needs and can create meaningful market impact.
Focus narrative
CHV invests in early-stage companies, particularly from seed through Series B stages, that are developing breakthrough medical technologies. The firm is especially interested in companies transitioning from pre-clinical to clinical development, emphasizing capital efficiency, strong technological foundations, clear regulatory pathways, and scalable business models. While agnostic to specific therapeutic areas, CHV seeks high-value medical devices that can significantly impact healthcare.
Value beyond capital
CHV adds value to its portfolio companies by acting as a first institutional investor, leading or co-leading investments, and providing ongoing support through product development, clinical milestones, and regulatory execution. The firm helps assemble complementary syndicates and offers access to a robust network, ensuring that entrepreneurs have the necessary guidance and resources to succeed.
Focus and fit
- Stages
- Seed · Series A · Series B
- Sectors
- Healthcare · Digital Health · Diagnostics
- Regions
- North America · Global
Availability
- Currently deploying
- Not published
Portfolio and track record
- Recorded notable exits
- Veracyte, Inc., Boston Scientific, Agilent Technologies, Life Technologies, and AngioDynamics
Portfolio context
CHV's portfolio includes notable companies such as Veracyte, Inc. (NASDAQ: VCYT), Boston Scientific (NYSE: BSX), Agilent Technologies (NYSE: A), Life Technologies (NYSE: TMO), Medline Systems, and AngioDynamics (NASDAQ: ANGO). Other portfolio companies include ARIA CV, AtaCor Medical, Avive, Brixton Biosciences, Conformal Medical, Esperto Medical, EyeCool Therapeutics, Instylla, Rejoni, and Venova Medical.
Common questions
What to know about CHV
Upseed classifies CHV under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 1, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.